tbuckley/cabot-search huggingface dataset:
<i>Announcement</i>: National Stroke Awareness Month — May 2016
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

May is National Stroke Awareness Month, an observance that raises awareness of the signs and symptoms of stroke and encourages persons to act FAST (Face drooping, Arm weakness, Speech difficulty, Time to call 911) if someone is having a stroke. Stroke is the fifth leading cause of death in the United States and a leading cause of severe disability (1,2). In the United States, one person dies from stroke every 4 minutes (2).
Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group
Authors: R. Dagan
Journal: JAMA (1992)

<h3>Objective.</h3> —To study the epidemiology of childhood pneumococcal invasive infections in Israel as a background for immunization programs. <h3>Design.</h3> —A 2-year (October 1988 through September 1990) prospective, nationwide surveillance of all invasive pediatric pneumococcal infections. <h3>Setting.</h3> —All 25 medical centers hospitalizing children in Israel, including all laboratories performing blood cultures from pediatric patients. <h3>Patients.</h3> —Infants and children aged 0 to 12 years visiting the pediatric emergency department or hospitalized in pediatric departments were included if<i>Streptococcus pneumoniae</i>was isolated from blood or cerebrospinal fluid. <h3>Results.</h3> —Four hundred sixty-nine invasive infections were diagnosed. Pneumonia, bacteremia without apparent focus, meningitis, and cellulitis were found in 39%, 37%, 17%, and 3%, respectively. The annual incidence was 42 per 100000 for children younger than 5 years of age (104 per 100000 for those &lt;12 months old). The two most common serotypes were 1 and 5, which are rare in Western Europe and North America. Eight groups comprised 82% of all invasive infections. Extrapolated to a population in which 100 000 live births occur yearly, the total annual hospitalizations for pneumococci infections was calculated to be 1928 days. The overall case-fatality rate was 2.2%, but it was 30% during the first month of life. <h3>Conclusions.</h3> —Pneumococcal invasive infections are common in children in Israel and carry considerable morbidity. (<i>JAMA</i>. 1992;268:3328-3332)
Renal Polycythemia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Announcements
Authors: Scott B. Patten, Luanne M. Metz, James E. Aikens, Theresa A. Kiolbasa, Robert Sobel, Alvise Orlandini, Matteo Rocco Pastore, Andrea Fossati, Stefano Clerici, Alessandro Sergi, Annalisa Balini, Cesare Maffei, Antonio Secchi, Guido Pozza, Isao Fukunishi, Masaki Hattori, Douglas Berger, Isao Fukunishi, Mary Alice O'Dowd, Giovanni A. Fava, Ludwig Teusch, Hildegard Böhme, Markus Gastpar, Takashi Hosaka, Tomifusa Kuboki, Yoshihiro Ishikawa, Ernest H. Friedman
Journal: Psychotherapy and Psychosomatics (1997)
Driving Licences
Authors: E. C. O. Jewesbury
Journal: BMJ (1958)

Glycine is a simple nonessential amino acid known to have neuroprotective properties. Treatment with glycine results in reduced infarct volume of the brain, neurologic function scores, and neuronal and microglial death in ischemic stroke injury. Neuroinflammation has been considered a major contributor to cerebral ischemia–induced brain damage. However, the role of glycine in neuroinflammation following ischemic stroke is unclear. The present study aimed to determine whether neuroinflammation is involved in the neuroprotective effects of glycine in cerebral ischemia injury. Ischemic stroke promotes M1 microglial polarization. Interestingly, we found that the injection of glycine in rats after injury can inhibit ischemia-induced inflammation and promote M2 microglial polarization in vivo (Sprague–Dawley rats) and in vitro (cortical microglia and BV-2 cells). We show that glycine suppresses Hif-1α by inhibiting the upregulation of NF-κB p65 after ischemia-reperfusion injury, resulting in the inhibition of proinflammatory activity. The activation of AKT mediates the inhibition of NF-κB p65/Hif-1α signaling by glycine. Moreover, we confirm that glycine-regulated AKT activation is mediated by the inhibition of PTEN in a PTEN depletion cell line, U251 cells. Glycine modulates microglial polarization after ischemic stroke, which indirectly inhibits ischemia-induced neuronal death and functional recovery. Taken together, our findings provide a new understanding of glycine in neuroprotection by inhibiting M1 microglial polarization and promoting anti-inflammation by suppressing NF-κB p65/Hif-1α signaling.
Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.
Authors: Scott F. Huntington, Gottfried Raffael Von Keudell, Amy J. Davidoff, Cary Philip Gross, Sapna A Prasad
Journal: Journal of Clinical Oncology (2018)

6609 Background: In a recent randomized, open-label trial (ECHELON-1), brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (A+AVD) decreased the risk of progression in adults diagnosed with stage III/IV Hodgkin lymphoma (HL) compared to standard bleomycin-containing chemotherapy (ABVD). However, the cost-effectiveness of incorporating brentuximab vedotin into the first-line setting is unknown. Methods: We constructed a Markov decision-analytic model to measure the costs and clinical outcomes for A+AVD compared to ABVD as first-line therapy in a cohort of patients with stage III/IV HL. Progression-free survival and transition probabilities were estimated from ECHELON-1 by fitting parametric survival distributions. Centers for Medicare & Medicaid Drug Pricing Files from December 2017 were used for drug costs (106% of average sales price). Additional expenditures and clinical utilities were estimated from literature. Lifetime direct health care costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for A+AVD compared with ABVD from a societal perspective within the United States. Our model was also used to estimate price reductions of brentuximab vedotin that would achieve more favorable cost-effectiveness under indication-specific pricing. Results: A+AVD was associated with an improvement of 0.48 QALYs compared to treatment with standard ABVD. However, incorporating brentuximab vedotin into first-line therapy led to significantly higher lifetime costs ($334,863 versus $193,780), causing the ICER for A+AVD compared with ABVD to be $292,266/QALY. If indication-specific pricing was implemented, price reductions of brentuximab vedotin by 40% to 60% in the first-line setting would produce ICERs of $100,000 to $150,000/QALY. Conclusions: Substituting brentuximab vedotin for bleomycin during first-line therapy for stage III/IV HL is unlikely to be cost-effective under current drug pricing. Should indication-specific pricing be implemented, discounting brentuximab vedotin in the first-line setting by 40% to 60% could reduce ICERs to widely acceptable values.
Clinical characteristics and treatment outcomes of patients (pts) with advanced germ cell tumor (aGCT) treated at a tertiary cancer center in Brazil.
Authors: Vitor Fiorin de Vasconcellos, Diogo Assed Bastos, Allan Andresson Lima Pereira, Bruno Rodriguez Pereira, Jamile Almeida Silva, David Queiroz Borges Muniz, Giuliano Guglielmetti, William Carlos Nahas, Carlos Dzik
Journal: Journal of Clinical Oncology (2018)

568 Background: Reported treatment outcomes for pts with aGCT are largely based on series from developed countries. Data from less developed countries are lacking. Methods: From 2000 to 2015, a retrospective analysis identified 302 pts with aGCT treated at Instituto do Cancer do Estado de São Paulo (ICESP). Kaplan-Meier methods were used for analysis of progression-free survival (PFS) and overall survival (OS) according to the International Germ Cell Consensus Classification Group (IGCCCG). Results: Median follow-up was 46 months and median age was 28 years old. Clinical features and management are detailed in the Table. 54 pts (18%) had ECOG performance status (PS) ≥ 2 at baseline. According to the IGCCCG, 57% were good-, 18.3% intermediate-, and 24.7% poor-risk disease. Median AFP was 2.9, 243, and 3.998 and HCG was 0.4, 113 and 301 in IGCCCG good-, intermediate-, and poor-risk groups, respectively. 5-year PFS and OS were 69% and 85%, respectively, including 83% and 95.3% in good-risk, 70.9% and 83.6% in intermediate-risk and 35.1% and 62.2% in poor-risk pts. Only 3 pts (3%) received high-dose chemotherapy (HDCT) as first salvage therapy. Conclusions: Brazilian pts with advanced GCT in this cohort had similar outcomes as pts in the IGCCCG database. In comparison to contemporary series, pts with intermediate- and poor-risk GCT had slightly inferior PFS and OS, possibly due to a high percentage of pts with poor PS and less use of HDCT. [Table: see text]
PIERSON W. BANNING—INTERNATIONAL FAKER
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Introduction
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JEALOUSY AS A DISEASE.
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Percentum Solutions in Pharmacy.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML
Authors: Jessica A Pollard, Todd Alonzo, Robert Gerbing, Susana C. Raimondi, Betsy Hirsch, Janet Franklin, Alan Gamis, Michael R Loken, Soheil Meshinchi
Journal: Blood (2008)
Correction to: Once-Daily versus Twice Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies
Authors: Somratai Vadcharavivad, Warangkana Saengram, Annop Phupradit, Nalinee Poolsup, Wiwat Chancharoenthana
Journal: Drugs (2019)

The row for study Jelassi et al. (2011) [28], where the Observational Period for ER-Tac reads June 2007–March 2010a and for IR-Tac reads N/A.
Treatment for Newly Diagnosed Hypertension: Patterns of Prescribing and Antihypertensive Effectiveness in the UK
Authors: Tom Walley, Andy K Duggan, Alan R Haycox, Christie J Niziol
Journal: Journal of the Royal Society of Medicine (2003)

Improved practice in the management of hypertension depends on an understanding of existing patterns of treatment. To describe the management of newly diagnosed hypertension in British general practice and the effectiveness of current prescribing patterns we conducted a retrospective observational study using data from a computerized general practitioner record database (DIN-LINK). 21 024 patients were first treated for newly diagnosed hypertension between January 1993 and December 1997, and were followed for 4 years. Diuretics or beta-blockers were the most widely prescribed first-line treatments, used in 54% of patients. The mean continuation rate for first-line therapy was 69% at 12 months: the continuation rate was highest for angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists. After 12 months of treatment the mean blood pressure reduction was 19/10 mmHg. Blood pressure targets were met in only 14% of patients. After 48 months of treatment 34% of patients had not improved in band of blood pressure severity. Many patients with severe hypertension at 12 months were still being prescribed only one drug. The lack of aggression in antihypertensive treatment, indicated by the low number of agents prescribed and the failure to achieve targets, is disappointing. Prescribing patterns for first-line therapy corresponded to guidelines. Continuation rates on first-line therapy were higher than often reported. The choice of drug for additions to or switches from first-line therapy had no clear pattern. Routinely collected computerized data could be used to support clinical governance activities in primary care.
Joint study of extracranial arterial occlusion. VI. Racial differences in hospitalized patients with ischemic stroke
Authors: A. Heyman
Journal: JAMA (1972)

An analysis was made of 5,593 white and 911 black patients in the Joint Study of Extracranial Arterial Occlusion to determine the difference in clinical and arteriographic manifestations of ischemic stroke in the two groups. Black patients were found to have a higher frequency of occlusive disease of the intracranial arteries, whereas white patients were more likely to have lesions in the extracranial arteries. Blacks differed from whites in their neurologic manifestations, with a lower incidence of transient ischemic symptoms and a greater frequency of completed stroke. Severe hypertension was noted in 40% of the black patients and only 26% of the white patients. In general, the age of blacks on admission was younger than that of whites.
Successful Homotransplantation of the Human Kidney Between Identical Twins
Authors: John P. Merrill
Journal: JAMA (1984)

A patient whose illness had begun with edema and hypertension was found to have suffered extreme atrophy of both kidneys. Because of the steady worsening of the condition and the appearance of uremia with other unfavorable prognostic signs, transplantation of one kidney from the patient's healthy identical twin brother was undertaken. Preparations included collection of evidence of monozygosity and experimental transplantation of a skin graft from the twin. During the transfer of the healthy kidney it was totally ischemic for 82 minutes. Evidence of functional activity in the transplanted kidney was obtained. The hypertension persisted until the patient's diseased kidneys were both removed. The homograft has survived for 11 months, and the marked clinical improvement in the patient has included disappearance of the signs of malignant hypertension.
Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in estrogen receptor-positive breast cancer.
Authors: Ji sun Kim, Wonshik Han, Jee Man You, Hee-Chul Shin, Soo Kyung Ahn, Hyeong Gon Moon, Seock-Ah Im, Tae-You Kim, Nariya Cho, Woo Kyung Moon, Dong Young Noh
Journal: Journal of Clinical Oncology (2012)

e21160 Background: Previous studies showed that anti-estrogen therapy lowers mammographic breast density (MD). We hypothesized that the short-term change of breast density can be a surrogate marker predicting response to adjuvant endocrine therapy (ET) for breast cancer. Methods: We analyzed data of 1,065 estrogen receptor (ER)-positive breast cancer patients who underwent surgery between 2003 and 2006 and received at least 2 years of ET including tamoxifen and aromatase inhibitor. MD was measured using Cumulus software 4.0 and expressed as a percentage. MD reduction was defined as an absolute difference between the MD of two mammography images: taken preoperatively and 8-20months after the start of adjuvant ET.. Results: After median follow up of 68.8 months, overall recurrence rate was 7.5% (80/1065). Mean MD reduction was 5.9% (-17.2 to 36.9). In a logistic regression analysis, age&lt;50, high preoperative MD, and longer interval between start of ET to the 2 nd mammogram were significantly associated with higher MD reduction (p value&lt;0.05). In a survival analysis using Cox model, tumor size (&gt;2cm), lymph node positive, high Ki-67 (≥10%), and lower MD reduction were independent factors significantly associated with recurrence-free survival (p&lt;0.05). The hazard of recurrence increased proportionally according to the less degree of MD reduction. Conclusions: MD change during short-term use of adjuvant ET was a significant predictive factor for long-term recurrence in ER-positive breast cancer. It is urgent to develop effective treatment strategy in patients who have less MD reduction in spite of about 1 year of ET.
Principles of Ambulatory Medicine
Authors: Harold Nachimson
Journal: JAMA (1991)

This important and timely third edition of a well-established text in ambulatory medicine is welcome. Although large and voluminous, it is thinner than the previous edition, owing to modern publishing techniques. The textbook essentially follows the format established in the two previous editions, with 15 sections of 102 chapters, the sections grouped clinically (eg, pulmonary problems, gynecologic problems). The preface to the first edition set the stage for the text's most likely beneficiaries, and this edition continues the tradition: "This book is directed primarily toward the general physicians who care for adult ambulatory patients." Don't look for pediatrics, surgical techniques, or such. The introductory chapter, as in past editions, defines and characterizes the distinct domain of ambulatory medicine. General and family physicians, as a group, will minister to about 30% of all patient office visits (based on 1985 data). An interesting quoted comment is Balint's: "... by far the most frequently
The Lumleian Lectures on the Tongue as an Indication of Disease
Authors: W. H. Dickinson
Journal: BMJ (1888)

THE knowledge wvhich enables many a practical physician to make the tongue an index of diagnosis, treatment, and prognosis is, for the most part, unwritteni.It has been handed down to us as part of the tradition of the elders, and few attempts have been made to analyse or educe laws from the accumulation of experience of which it consists.The labour which has been bestowed